2024 Corporate Therapeutic Symposia Schedule
Non-Accredited
Lunch will be served during all Corporate Therapeutic Symposia.
Friday, September 27, 2024, 13:30 - 14:30
The First-Line Prescription Treatment for Hallucinations and Delusions Associated With Parkinson's Disease Psychosis
Acadia Pharmaceuticals Inc.
Meeting Room 103 AB, Ground Level
Dr. Kremens and Dr. Isaacson will discuss educational information about hallucinations and delusions associated with Parkinson’s disease (PD) psychosis, including the symptoms of PD psychosis, a non-motor aspect of PD, and how they progress over time; the impact and burden of PD psychosis on patients, their caregivers, and society; and the relevant treatment considerations when addressing PD psychosis. Dr. Kremens and Dr. Isaacson will also review clinical efficacy for a treatment option and real-world evidence from retrospective analyses investigating the risk of all-cause mortality among patients with PD psychosis treated with atypical antipsychotics. Meal will be served.
Innovation in “On” time is Here: Introducing CREXONT® (carbidopa and levodopa) Extended-Release Capsules
Amneal Pharmaceuticals LLC
Meeting Room 108 AB, Ground Level
Join us for an expert-led presentation that will review the efficacy, safety, and dosing of CREXONT, a new oral CD/LD therapy that features novel extended-release technology. Learn how to individualize CREXONT dosing through patient case examples. Attendees will also have the opportunity to ask the faculty questions about the data presented.
SKYCLARYS, the First and Only FDA-Approved Prescription Treatment for Friedreich Ataxia in Adults and Adolescents Aged 16 Years and Older
Biogen
Meeting Room 113 AB, Ground Level
This presentation will include an introduction into the clinical background of Friedreich Ataxia (FA), a summary of the clinical efficacy and safety data from the clinical trials that studied SKYCLARYS in the treatment of FA, and the clinical management of treatment with SKYCLARYS.
Saturday, September 28, 2024, 13:30 - 14:30
Time to Redefine the Paradigm for Advanced Parkinson’s Disease
AbbVie
Meeting Room 108 AB, Ground Level
In this educational platform our panel of experts will address the importance of taking a holistic view on the burden of Advanced Parkinson’s Disease (aPD) as a 24 hour disease and how to identify patients uncontrolled on oral medications.
Maneuvering the OFF: How to Facilitate Quick Relief for Off-Episodes in Parkinson’s Disease
Merz Therapeutics GmbH
Meeting Room 103 AB, Ground Level
This symposium will explore the critical issue of OFF episodes in Parkinson’s disease and summarize possible solutions for rapid treatment. The discussion will shed light on the motor challenges patients face during these OFF episodes and explore effective ways to alleviate them. Our esteemed faculty will also examine FDA-approved on-demand therapies and their use alongside baseline oral medications. Lastly, we’ll engage in a round-table discussion about an on-demand therapy and identify patient profiles that stand to benefit the most.
Sunday, September 29, 2024, 13:00 - 14:00
MTPA Corporate Therapeutic Symposium
Mitsubishi Tanabe Pharma America
Meeting Room 113 AB, Ground Level
Description TBA.
Controversy and Consensus: Treating Dyskinesia When Managing OFF
Supernus Pharmaceuticals Inc.
Meeting Room 108 AB, Ground Level
Description TBA.
DAXXIFY® for Cervical Dystonia: From Clinical Trials to Real World Experience
Revance Therapeutics
Meeting Room 103 AB, Ground Level
Please join us to learn about the DAXXIFY® Difference with Laxman Bahroo, DO, FAAN, Aaron L. Ellenbogen, DO, MPH, Diego Torres-Russotto, MD, FAAN, and Conor Gallagher, PhD. The faculty will review the science behind this neurotoxin’s unique formulation, the highlights of its clinical trial data, and engage in a panel discussion on real-world insights with DAXXIFY®.
Monday, September 30, 2024, 13:00 - 14:00
Pursuing the Right Balance: Dopamine Receptor Selectivity in Parkinson’s Disease
Cerevel Therapeutics
Meeting Room 108 AB, Ground Level
Cerevel Therapeutics invites you to spend an hour with three scientific thought leaders in the field of Parkinson’s disease. During this symposium our expert speakers will: - Describe the role of dopamine receptors in PD and current pharmacological treatment approaches in early and advancing PD- Discuss the potential clinical implications of selectively targeting D1/D5 dopamine receptors in people with PD- Explore ongoing clinical development programs for novel treatments for PD.